Cart is empty A new clinical tool developed by a team of researchers led by the Dana-Farber Cancer Institute pinpoints which Clonal hematopoiesis patients are at highest risk for cancer progression. Their work was published this week in NEJM Evidence.
A new clinical tool developed by a team of researchers led by the Dana-Farber Cancer Institute pinpoints which Clonal hematopoiesis patients are at highest risk for cancer progression. Their work was published this week in NEJM Evidence.
Leave A Comment